Key points are not available for this paper at this time.
Clinical trials are an essential component of drug development for new cancer treatments, yet the information required to determine a patient's eligibility for enrollment is scattered in large amounts of unstructured text. Genomic biomarkers are especially important in precision medicine and targeted therapies, making them essential for matching patients to appropriate trials. Large language models (LLMs) offer a promising solution for extracting this information from clinical trial data, aiding both physicians and patients in identifying suitable matches. In this study, we explore various LLM strategies for extracting genetic biomarkers from oncology trials to improve patient enrollment rates. Our results show that open-source language models, when applied out-of-the-box, effectively capture complex logical expressions and structure genomic biomarkers in disjunctive normal form, outperforming closed-source models such as GPT-4 and GPT-3.5-Turbo. Furthermore, fine-tuning these open-source models with additional data significantly enhances their performance.
Khoury et al. (Thu,) studied this question.